Beta adrenoceptor agonists, clenbuterol, and isoproterenol retard denervation atrophy in rat gastrocnemius muscle: use of 3-methylhistidine as a marker of myofibrillar degeneration.
The effects of beta adrenergic agonists, clenbuterol (2 mg/kg body weight/d) and isoproterenol (12 mg/kg body weight/d), in normal innervated and denervated rat gastrocnemius muscle were investigated. The daily administration of beta adrenergic agonists to normal innervated rats for a short period (7 d) resulted in the hypertrophy of gastrocnemius as confirmed from the measurement of total tissue protein contents. The development of denervation atrophy witnessed a stimulation in the expression of acid and alkaline phosphatases, pointing to an enhanced myofibrillar degeneration. An administration of beta adrenergic agonists inhibited the expression of raised levels of these enzymes in denervated muscle. A measurement of 3-methylhistidine in muscle revealed a loss of amino acid with the progress in the development of denervation atrophy. Serum and urine samples from denervated rats showed a progressive accumulation of 3-methylhistidine. Clenbuterol and isoproterenol treatment to these rats resulted in an inhibition of 3-methylhistidine accumulation. When 3-methylhistidine was used as a marker of myofibrillar degeneration, the results seemed to suggest that the degeneration of cyto-contractile apparatus accompanying denervation atrophy is attenuated in the presence of beta adrenergic agonists, implying that these sympathomimetic drugs are capable of reversing denervation atrophy in rat gastrocnemius.
Agrawal
Sapna
S
Department of Biosciences, Himachal Pradesh University, Summer Hill, Shimla-171 005, India.
Thakur
Pushpa
P
Katoch
Surender S
SS
D000135:Acid Phosphatase / Q000378:metabolism; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000469:Alkaline Phosphatase / Q000378:metabolism; D000596:Amino Acids / Q000097:blood / Q000652:urine; D000818:Animals; D015415:Biomarkers; D002976:Clenbuterol / Q000494:pharmacology*; D007545:Isoproterenol / Q000494:pharmacology*; D008297:Male; D008762:Methylhistidines / Q000378:metabolism; D009121:Muscle Denervation / Q000009:adverse effects*; D009124:Muscle Proteins / Q000378:metabolism; D018482:Muscle, Skeletal / Q000201:enzymology / Q000294:innervation* / Q000378:metabolism; D009133:Muscular Atrophy / Q000517:prevention & control*; D009210:Myofibrils / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar
D000318:Adrenergic beta-Agonists; D000596:Amino Acids; D015415:Biomarkers; D008762:Methylhistidines; D009124:Muscle Proteins; D000469:Alkaline Phosphatase; D000135:Acid Phosphatase; D007545:Isoproterenol; C028118:3-methylhistidine; D002976:Clenbuterol